Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month – CNBC

Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month  CNBC Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay Patients  Bloomberg.com Novo Nordisk further lowers prices for weight loss, diabetes drugs for those who pay cash  CNN LifeMD® to Offer Market-Leading Pricing for GLP-1  GlobeNewswire Novo Nordisk rolls out $349 Wegovy cash price ahead of plan  Reuters

Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ

Eli Lilly LLY and Johnson & Johnson JNJ are major U.S. healthcare companies within the pharmaceutical/biotech space. Both companies have a strong presence in oncology, immunology and neuroscience areas. J&J also has drugs for cardiovascular and metabolic diseases, pulmonary hypertension and infectious diseases, along with a strong presence in the medical devices segment. Lilly boasts a […]

Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay Patients – Bloomberg.com

Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay Patients  Bloomberg.com Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month  CNBC Novo Nordisk further lowers prices for weight loss, diabetes drugs for those who pay cash  CNN LifeMD® to Offer Market-Leading Pricing for GLP-1  GlobeNewswire Novo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 […]

Macter gaining market share, and diversifying into cosmetics

Macter International Ltd has emerged from the latest results season with a clear message for investors: momentum is back in branded generics, new biologics are scaling, and a bet on consumer beauty is moving from trial to traction. Management says the company is growing faster than the market, based on data from the healthcare data […]